substituent selected from halogen, CN, $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $C_1$-$C_6$ fluoroalkyl or $C_1$-$C_6$ alkoxy; and

$R^1$ is one or more hydrogen, halogen, $C_1$-$C_3$ fluoroalkyl or $C_1$-$C_3$ alkyl;

or a pharmaceutically acceptable salt thereof.

In one embodiment the present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in therapy.

The present invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

In one embodiment the invention provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a neurodegenerative or cognitive disorder.

In one embodiment, the invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in a method for the treatment of a neurodegenerative or cognitive disorder.

In one embodiment the present disclosure provides a method of treating a neurodegenerative or cognitive disorder comprising administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof to a patient in need thereof.

Further embodiments of the invention are provided immediately below:

In one embodiment, the compound of the present invention is of formula Ia or Ib




Formula Ia




Formula Ib

or a pharmaceutically acceptable salt thereof.

In one embodiment, $R^1$ is F or H, particularly F.

In one embodiment, the compound of the present invention is of Formula Ia and $R^1$ is F.

In one embodiment, Ar is optionally substituted with one or more substituents selected from F, Cl, Br, CN, $C_1$-$C_3$ alkyl, $C_1$-$C_3$ fluoroalkyl or $C_1$-$C_3$ alkoxy.

In one embodiment, Ar is optionally substituted phenyl.

In one embodiment, Ar is optionally substituted pyridyl.

In one embodiment, Ar is optionally substituted pyrimidyl.

In one embodiment, Ar is optionally substituted pyrazinyl.

14. The use of a compound according to anyone of claims 1-12 for the manufacture of a medicament for treating a disease selected from Alzheimer's disease (familial or sporadic), preclinical Alzheimer's disease, prodromal Alzheimer's disease, mild cognitive impairment, Down's synsdrome and cerebral amyloid angiopathy.

15. A compound according aaccording to anyone of claims 1-12 for use in therapy.